In the world of biotech stocks, CRISPR Therapeutics, Zealand Pharma, and Viking Therapeutics are identified as potential monster stocks with significant growth potential. CRISPR Therapeutics recently achieved a milestone with the approval of Casgevy for treating sickle cell disease and thalassemia. Zealand Pharma, on the other hand, has two weight loss drugs showing promising results in trials. Viking Therapeutics is also making waves with positive results from its obesity and NASH treatments. These companies have the potential to become major players in the biotech industry.

Investors are advised to consider the growth potential of these biotech stocks, as they could offer significant returns in the coming years. While CRISPR Therapeutics, Zealand Pharma, and Viking Therapeutics are not without risks, their innovative approaches and strong pipelines position them as potential leaders in the industry. It’s essential to conduct thorough research and consider all factors before investing in these companies.

Read more at Nasdaq: 3 Monster Stocks in the Making to Buy Right Now